Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
06 2022
Historique:
received: 02 12 2021
revised: 20 01 2022
accepted: 28 02 2022
pubmed: 28 3 2022
medline: 18 5 2022
entrez: 27 3 2022
Statut: ppublish

Résumé

Disability and mortality burden of non-communicable diseases (NCDs) have risen worldwide; however, the NCD burden among adolescents remains poorly described in the EU. Estimates were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Causes of NCDs were analysed at three different levels of the GBD 2019 hierarchy, for which mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were extracted. Estimates, with the 95% uncertainty intervals (UI), were retrieved for EU Member States from 1990 to 2019, three age subgroups (10-14 years, 15-19 years, and 20-24 years), and by sex. Spearman's correlation was conducted between DALY rates for NCDs and the Socio-demographic Index (SDI) of each EU Member State. In 2019, NCDs accounted for 86·4% (95% uncertainty interval 83·5-88·8) of all YLDs and 38·8% (37·4-39·8) of total deaths in adolescents aged 10-24 years. For NCDs in this age group, neoplasms were the leading causes of both mortality (4·01 [95% uncertainty interval 3·62-4·25] per 100 000 population) and YLLs (281·78 [254·25-298·92] per 100 000 population), whereas mental disorders were the leading cause for YLDs (2039·36 [1432·56-2773·47] per 100 000 population) and DALYs (2040·59 [1433·96-2774·62] per 100 000 population) in all EU Member States, and in all studied age groups. In 2019, among adolescents aged 10-24 years, males had a higher mortality rate per 100 000 population due to NCDs than females (11·66 [11·04-12·28] vs 7·89 [7·53-8·23]), whereas females presented a higher DALY rate per 100 000 population due to NCDs (8003·25 [5812·78-10 701·59] vs 6083·91 [4576·63-7857·92]). From 1990 to 2019, mortality rate due to NCDs in adolescents aged 10-24 years substantially decreased (-40·41% [-43·00 to -37·61), and also the YLL rate considerably decreased (-40·56% [-43·16 to -37·74]), except for mental disorders (which increased by 32·18% [1·67 to 66·49]), whereas the YLD rate increased slightly (1·44% [0·09 to 2·79]). Positive correlations were observed between DALY rates and SDIs for substance use disorders (r NCD-related mortality has substantially declined among adolescents in the EU between 1990 and 2019, but the rising trend of YLL attributed to mental disorders and their YLD burden are concerning. Differences by sex, age group, and across EU Member States highlight the importance of preventive interventions and scaling up adolescent-responsive health-care systems, which should prioritise specific needs by sex, age, and location. Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
Disability and mortality burden of non-communicable diseases (NCDs) have risen worldwide; however, the NCD burden among adolescents remains poorly described in the EU.
METHODS
Estimates were retrieved from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Causes of NCDs were analysed at three different levels of the GBD 2019 hierarchy, for which mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were extracted. Estimates, with the 95% uncertainty intervals (UI), were retrieved for EU Member States from 1990 to 2019, three age subgroups (10-14 years, 15-19 years, and 20-24 years), and by sex. Spearman's correlation was conducted between DALY rates for NCDs and the Socio-demographic Index (SDI) of each EU Member State.
FINDINGS
In 2019, NCDs accounted for 86·4% (95% uncertainty interval 83·5-88·8) of all YLDs and 38·8% (37·4-39·8) of total deaths in adolescents aged 10-24 years. For NCDs in this age group, neoplasms were the leading causes of both mortality (4·01 [95% uncertainty interval 3·62-4·25] per 100 000 population) and YLLs (281·78 [254·25-298·92] per 100 000 population), whereas mental disorders were the leading cause for YLDs (2039·36 [1432·56-2773·47] per 100 000 population) and DALYs (2040·59 [1433·96-2774·62] per 100 000 population) in all EU Member States, and in all studied age groups. In 2019, among adolescents aged 10-24 years, males had a higher mortality rate per 100 000 population due to NCDs than females (11·66 [11·04-12·28] vs 7·89 [7·53-8·23]), whereas females presented a higher DALY rate per 100 000 population due to NCDs (8003·25 [5812·78-10 701·59] vs 6083·91 [4576·63-7857·92]). From 1990 to 2019, mortality rate due to NCDs in adolescents aged 10-24 years substantially decreased (-40·41% [-43·00 to -37·61), and also the YLL rate considerably decreased (-40·56% [-43·16 to -37·74]), except for mental disorders (which increased by 32·18% [1·67 to 66·49]), whereas the YLD rate increased slightly (1·44% [0·09 to 2·79]). Positive correlations were observed between DALY rates and SDIs for substance use disorders (r
INTERPRETATION
NCD-related mortality has substantially declined among adolescents in the EU between 1990 and 2019, but the rising trend of YLL attributed to mental disorders and their YLD burden are concerning. Differences by sex, age group, and across EU Member States highlight the importance of preventive interventions and scaling up adolescent-responsive health-care systems, which should prioritise specific needs by sex, age, and location.
FUNDING
Bill & Melinda Gates Foundation.

Identifiants

pubmed: 35339209
pii: S2352-4642(22)00073-6
doi: 10.1016/S2352-4642(22)00073-6
pmc: PMC9090900
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-383

Subventions

Organisme : Medical Research Council
ID : MR/S011676/1
Pays : United Kingdom

Investigateurs

Benedetta Armocida (B)
Lorenzo Monasta (L)
Susan M Sawyer (SM)
Flavia Bustreo (F)
Giulia Segafredo (G)
Giulio Castelpietra (G)
Luca Ronfani (L)
Maja Pasovic (M)
Simon I Hay (SI)
Derrick Bary Abila (DB)
Hassan Abolhassani (H)
Manfred Mario Kokou Accrombessi (MMK)
Victor Adekanmbi (V)
Keivan Ahmadi (K)
Hanadi Al Hamad (H)
Mamoon A Aldeyab (MA)
Adel Al-Jumaily (A)
Robert Ancuceanu (R)
Catalina Liliana Andrei (CL)
Tudorel Andrei (T)
Ashokan Arumugam (A)
Sameh Attia (S)
Avinash Aujayeb (A)
Marcel Ausloos (M)
Jennifer L Baker (JL)
Francesco Barone-Adesi (F)
Fabio Barra (F)
Sandra Barteit (S)
Sanjay Basu (S)
Bernhard T Baune (BT)
Yannick Béjot (Y)
Luis Belo (L)
Derrick A Bennett (DA)
Boris Bikbov (B)
Andras Bikov (A)
Oleg Blyuss (O)
Susanne Breitner (S)
Hermann Brenner (H)
Giulia Carreras (G)
Márcia Carvalho (M)
Alberico L Catapano (AL)
Joht Singh Chandan (JS)
Periklis Charalampous (P)
Simiao Chen (S)
Joao Conde (J)
Natália Cruz-Martins (N)
Giovanni Damiani (G)
Anna Dastiridou (A)
Alejandro de la Torre-Luque (A)
Mostafa Dianatinasab (M)
Diana Dias da Silva (D)
Abdel Douiri (A)
Elena Dragioti (E)
Luchuo Engelbert Bain (L)
Adeniyi Francis Fagbamigbe (AF)
Seyed-Mohammad Fereshtehnejad (SM)
Pietro Ferrara (P)
José Miguel P Ferreira de Oliveira (JMP)
Simone Ferrero (S)
Lorenzo Ferro Desideri (L)
Florian Fischer (F)
Diogo A Fonseca (DA)
Piyada Gaewkhiew (P)
Santosh Gaihre (S)
Silvano Gallus (S)
Mariana Gaspar Fonseca (M)
Paramjit Singh Gill (PS)
James C Glasbey (JC)
Giuseppe Gorini (G)
Vijai Kumar Gupta (VK)
Mekdes Kondale Gurara (MK)
Josep Maria Haro (JM)
M Tasdik Hasan (MT)
Rasmus J Havmoeller (RJ)
Behzad Heibati (B)
Merel E Hellemons (ME)
Claudiu Herteliu (C)
Salman Hussain (S)
Gaetano Isola (G)
Olatunji Johnson (O)
Jost B Jonas (JB)
Jacek Jerzy Jozwiak (JJ)
Mikk Jürisson (M)
Zubair Kabir (Z)
André Karch (A)
Joonas H Kauppila (JH)
Gbenga A Kayode (GA)
Moien Ab Khan (MA)
Khaled Khatab (K)
Mika Kivimäki (M)
Miloslav Klugar (M)
Jitka Klugarová (J)
Kamrun Nahar Koly (KN)
Ai Koyanagi (A)
Om P Kurmi (OP)
Dian Kusuma (D)
Carlo La Vecchia (C)
Ben Lacey (B)
Tea Lallukka (T)
Demetris Lamnisos (D)
Berthold Langguth (B)
Anders O Larsson (AO)
Paolo Lauriola (P)
Paul H Lee (PH)
Matilde Leonardi (M)
An Li (A)
Christine Linehan (C)
Rubén López-Bueno (R)
Stefan Lorkowski (S)
Joana A Loureiro (JA)
Raimundas Lunevicius (R)
Laura A Magee (LA)
Francesca Giulia Magnani (FG)
Azeem Majeed (A)
Konstantinos Christos Makris (KC)
Alexander G Mathioudakis (AG)
Manu Raj Mathur (MR)
John J McGrath (JJ)
Ritesh G Menezes (RG)
Alexios-Fotios A Mentis (AA)
Atte Meretoja (A)
Tomislav Mestrovic (T)
Junmei Miao Jonasson (J)
Tomasz Miazgowski (T)
Andreea Mirica (A)
Marcello Moccia (M)
Shafiu Mohammed (S)
Mariam Molokhia (M)
Stefania Mondello (S)
Ulrich Otto Mueller (UO)
Francesk Mulita (F)
Daniel Munblit (D)
Ionut Negoi (I)
Ruxandra Irina Negoi (RI)
Evangelia Nena (E)
Nurulamin M Noor (NM)
Christoph Nowak (C)
George Ntaios (G)
Vincent Ebuka Nwatah (VE)
Bogdan Oancea (B)
Ayodipupo Sikiru Oguntade (AS)
Alberto Ortiz (A)
Adrian Otoiu (A)
Alicia Padron-Monedero (A)
Raffaele Palladino (R)
Adrian Pana (A)
Demosthenes Panagiotakos (D)
Songhomitra Panda-Jonas (S)
Shahina Pardhan (S)
Jay Patel (J)
Paolo Pedersini (P)
José L Peñalvo (JL)
Umberto Pensato (U)
Renato B Pereira (RB)
Norberto Perico (N)
Ionela-Roxana Petcu (IR)
Suzanne Polinder (S)
Maarten J Postma (MJ)
Mohammad Rabiee (M)
Navid Rabiee (N)
Alberto Raggi (A)
Shadi Rahimzadeh (S)
David Laith Rawaf (DL)
Salman Rawaf (S)
Faizan Ur Rehman (FU)
Giuseppe Remuzzi (G)
Abanoub Riad (A)
Alina Rodriguez (A)
Simona Sacco (S)
Mohammad Reza Saeb (MR)
Mahdi Safdarian (M)
Brijesh Sathian (B)
Davide Sattin (D)
Sonia Saxena (S)
Nikolaos Scarmeas (N)
Winfried Schlee (W)
Falk Schwendicke (F)
Morteza Shamsizadeh (M)
Nigussie Tadesse Sharew (NT)
Rahman Shiri (R)
Siddharudha Shivalli (S)
Velizar Shivarov (V)
João Pedro Silva (JP)
Colin R Simpson (CR)
Søren T Skou (ST)
Bogdan Socea (B)
Ireneous N Soyiri (IN)
Paschalis Steiropoulos (P)
Kurt Straif (K)
Xiaohui Sun (X)
Rafael Tabarés-Seisdedos (R)
Arulmani Thiyagarajan (A)
Fotis Topouzis (F)
Marcos Roberto Tovani-Palone (MR)
Thomas Clement Truelsen (TC)
Brigid Unim (B)
Jef Van den Eynde (J)
Tommi Juhani Vasankari (TJ)
Massimiliano Veroux (M)
Santos Villafaina (S)
Matej Vinko (M)
Francesco S Violante (FS)
Victor Volovici (V)
Yanzhong Wang (Y)
Ronny Westerman (R)
Mohammad Esmaeil Yadegarfar (ME)
Sanni Yaya (S)
Vesna Zadnik (V)
Alimuddin Zumla (A)
Pablo Perel (P)
David Beran (D)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Lancet Diabetes Endocrinol. 2018 Jan;6(1):69-80
pubmed: 28847479
Curr Opin Psychiatry. 2010 Jul;23(4):318-23
pubmed: 20540178
JAMA Pediatr. 2021 Nov 1;175(11):1142-1150
pubmed: 34369987
ESMO Open. 2017 Sep 8;2(4):e000252
pubmed: 29018578
Lancet. 2019 Mar 16;393(10176):1101-1118
pubmed: 30876706
Lancet. 2016 Jun 11;387(10036):2423-78
pubmed: 27174304
Aging Clin Exp Res. 2020 Jul;32(7):1189-1194
pubmed: 32458356
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
J Adolesc Health. 2013 Jun;52(6):670-81
pubmed: 23701887
BMC Public Health. 2020 Dec 14;20(1):1908
pubmed: 33317507
Lancet Glob Health. 2020 Dec;8(12):e1473-e1488
pubmed: 33091371
BMC Public Health. 2020 Sep 17;20(1):1415
pubmed: 32943028
Mol Psychiatry. 2022 Jan;27(1):281-295
pubmed: 34079068
Lancet Child Adolesc Health. 2018 Mar;2(3):223-228
pubmed: 30169257
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Lancet Child Adolesc Health. 2019 Nov;3(11):749
pubmed: 31564622
Lancet. 2012 Apr 28;379(9826):1630-40
pubmed: 22538178
Lancet Glob Health. 2016 Dec;4(12):e895-e896
pubmed: 27855860
Arch Dis Child. 2019 Mar;104(3):214-216
pubmed: 29599165
Lancet. 2021 Oct 30;398(10311):1593-1618
pubmed: 34755628
Lancet Child Adolesc Health. 2021 May;5(5):332-340
pubmed: 33675698
Lancet. 2012 Apr 28;379(9826):1641-52
pubmed: 22538179
BMJ. 2015 Sep 14;351:h4414
pubmed: 26371228
PLoS Med. 2016 Jun 28;13(6):e1002056
pubmed: 27351744
Lancet. 2007 May 5;369(9572):1565-1573
pubmed: 17482988
Eur Child Adolesc Psychiatry. 2014 Jul;23(7):611-20
pubmed: 24248753
Lancet. 2018 Apr 14;391(10129):1538-1548
pubmed: 29395268

Auteurs

Benedetta Armocida (B)

Division of Tropical and Humanitarian Medicine, University of Geneva, Geneva, Switzerland; Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.

Lorenzo Monasta (L)

Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy. Electronic address: lorenzo.monasta@burlo.trieste.it.

Susan Sawyer (S)

Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia; Murdoch Children's Research Institute, Melbourne, VIC, Australia; Centre for Adolescent Health, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.

Flavia Bustreo (F)

Fondation Botnar, Geneva, Switzerland.

Giulia Segafredo (G)

Medicines Patent Pool, Geneva, Switzerland.

Giulio Castelpietra (G)

Outpatient and Inpatient Care Service, Central Health Directorate, Friuli Venezia Giulia Region, Trieste, Italy.

Luca Ronfani (L)

Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.

Maja Pasovic (M)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Simon Hay (S)

Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.

Pablo Perel (P)

Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

David Beran (D)

Division of Tropical and Humanitarian Medicine, University of Geneva and Geneva University Hospitals, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH